Growth Hormone Treatment Does Not Alter Lower Limb Asymmetry in Children with Russell-Silver Syndrome

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background: Growth hormone (GH) treatment has been proven to have a beneficial effect on growth in children with Russell-Silver syndrome (RSS). Methods: We describe 7 prepubertal children with RSS and lower limb asymmetry treated with GH for 3 years. Results: There was a significant increase in height without any significant change in the asymmetry. Conclusions: We conclude that the rapid growth acceleration to GH treatment does not alter the lower limb asymmetry in children with RSS.

Related collections

Most cited references 1

Record: found
Abstract: found
Article: found

Growth Hormone Treatment in Growth Hormone-Sufficient and -Insufficient Children with Intrauterine Growth Retardation/Russell-Silver Syndrome

C Azcona, A Albanese, P Bareille … (1998)

Fifty-eight short prepubertal children with IUGR received GH treatment (mean dose: 28 IU/m 2 /week) for a mean (SEM) period of time of 3.4 (0.13) years (range 1–4 years). They were subdivided according to their GH response to a pharmacological test. Twenty-six were GH insufficient (GHI) (group 1) and 32 were non-GHI (group 2). At the commencement of GH therapy mean chronological age was 6.1 (0.4) years in both groups, mean height SDS (SEM) was –3.5 (0.2) in group 1 and –3.6 (0.2) in group 2, mean growth velocity (GV) SDS (SEM) was –1.9 (0.3) in group 1 and –0.3 (0.2) in group 2. GH therapy induced significant growth acceleration throughout the follow-up period without any significant differences between the two groups. GV SDS (SEM) increased to +3.0 (0.5) in group 1 and to +3.7 (0.4) in group 2 (p < 0.05 compared to baseline) during the first year of therapy. Subsequently, the growth-promoting effects of GH therapy diminished with time but GV remained significantly higher than baseline. This growth enhancement produced a significant rise in height SDS (SEM) reaching –1.4 (0.2) in group 1 and –1.7 (0.2) in group 2 after 4 years. In conclusion, our data did not show any significant differences in the growth response to GH therapy between GH-sufficient and -insufficient IUGR children who were only distinguishable by their GH secretion. This indicates that the decision to treat a short IUGR child with GH therapy should not be based upon the GH response to a provocative test.

0 comments Cited 13 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (publisher-id): HRE

Journal ID (nlm-ta): Horm Res Paediatr

Journal ID (doi): 10.1159/issn.1663-2818

Title: Hormone Research in Paediatrics

Publisher: S. Karger AG

ISSN (Print): 1663-2818

ISSN (Electronic): 1663-2826

Publication date Subscription-year: 2001

Publication date (Print): 2001

Publication date (Electronic): 15 February 2002

Volume: 56

Issue: 3-4

Pages: 114-116

Affiliations

Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children and Middlesex Hospital (UCLH), London, UK

Article

Publisher ID: 48102 Other ID: Horm Res 2001;56:114–116

DOI: 10.1159/000048102

PubMed ID: 11847473

SO-VID: 3d4dccd1-821e-4212-bb6d-ad6ee55a4584

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Growth Hormone Treatment Does Not Alter Lower Limb Asymmetry in Children with Russell-Silver Syndrome

Read this article at

Abstract

Related collections

Karger: Endocrinology

Most cited references 1

Growth Hormone Treatment in Growth Hormone-Sufficient and -Insufficient Children with Intrauterine Growth Retardation/Russell-Silver Syndrome

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 228

Cited by 2

Most referenced authors 9